A decade after cetuximab approval, anti-PD-1/PD-L1 checkpoint inhibitors are the first drugs to demonstrate prognostic benefits for the treatment of platinum-refractory recurrent or metastatic HNSCC and remain to be granted approval for treatment of primary and locally advanced HNSCC. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.